ABVC BioPharma ABVC

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.01 (-1.70%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of ABVC BioPharma (ABVC)
    ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.6386

    • Market Cap

      $15.13 Million

    • Price-Earnings Ratio

      -31.93

    • Total Outstanding Shares

      12.98 Million Shares

    • Total Employees

      19

    • Dividend

      $0.04 Per Share Quarterly

    • IPO Date

      November 9, 2004

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      44370 old warm springs blvd., Fremont, CA, 94538

    • Homepage

      https://www.abvcpharma.com

    Historical Stock Splits

    If you bought 3.712 shares of ABVC before June 9, 2005, you'd have 1 share today.
    Execution DateSplit Amount
    July 25, 20231-for-10 (Reverse Split)
    May 8, 20191-for-18 (Reverse Split)
    April 11, 20163.141-for-1
    December 28, 20105-for-1
    June 19, 20072.573255-for-1
    June 9, 20051.2-for-1

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$171,724
    Net Cash Flow From Financing Activities, Continuing$-145,393
    Net Cash Flow, Continuing$-1,546
    Exchange Gains/Losses$773
    Net Cash Flow From Investing Activities$-27,104
    Net Cash Flow From Investing Activities, Continuing$-26,331

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Revenues$389,276
    Income/Loss From Continuing Operations After Tax$-134,272
    Income/Loss From Continuing Operations Before Tax$-133,917
    Net Income/Loss Available To Common Stockholders, Basic$-186,561
    Net Income/Loss Attributable To Parent$-186,561
    Basic Average Shares$12.41 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-161,172
    Comprehensive Income/Loss$-161,172
    Other Comprehensive Income/Loss$-26,900
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Current Assets$2.15 Million
    Noncurrent Liabilities$167,881
    Equity Attributable To Parent$8.36 Million
    Current Liabilities$6.32 Million
    Wages$89,902
    Fixed Assets$7.93 Million

    Historical Dividends

    Current dividend: $0.04 Per Share Quarterly
    Announcement DatePayment DateRecord DateAmountFrequency
    Feb 26, 2013Apr 4, 2013Mar 8, 2013$0.039838Quarterly
    Dec 17, 2012Jan 29, 2013Dec 31, 2012$0.396951Biannually
    Dec 17, 2012Jan 29, 2013Dec 31, 2012$0.053907Quarterly
    Sep 21, 2012Oct 22, 2012Oct 3, 2012$0.206165Biannually
    Sep 21, 2012Oct 22, 2012Oct 3, 2012$0.054374Quarterly

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ABVC from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.